JP2020526515A - 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子 - Google Patents

遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子 Download PDF

Info

Publication number
JP2020526515A
JP2020526515A JP2020500140A JP2020500140A JP2020526515A JP 2020526515 A JP2020526515 A JP 2020526515A JP 2020500140 A JP2020500140 A JP 2020500140A JP 2020500140 A JP2020500140 A JP 2020500140A JP 2020526515 A JP2020526515 A JP 2020526515A
Authority
JP
Japan
Prior art keywords
mineral
interferon
ribonucleic acid
mineral layer
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020500140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526515A5 (https=
Inventor
ウィリアム・エル・マーフィー
アンドリュー・サリム・カイル
シャオホア・ユー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of JP2020526515A publication Critical patent/JP2020526515A/ja
Publication of JP2020526515A5 publication Critical patent/JP2020526515A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020500140A 2017-07-05 2018-07-05 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子 Pending JP2020526515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762528566P 2017-07-05 2017-07-05
US62/528,566 2017-07-05
PCT/US2018/040928 WO2019010310A1 (en) 2017-07-05 2018-07-05 MINERAL-COATED MICROPARTICLES FOR CO-ADMINISTRATION OF ANTI-INFLAMMATORY MOLECULES AND NUCLEIC ACIDS TO IMPROVE GENE DELIVERY RESULTS

Publications (2)

Publication Number Publication Date
JP2020526515A true JP2020526515A (ja) 2020-08-31
JP2020526515A5 JP2020526515A5 (https=) 2021-08-05

Family

ID=64950341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020500140A Pending JP2020526515A (ja) 2017-07-05 2018-07-05 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子

Country Status (6)

Country Link
US (2) US11065208B2 (https=)
EP (1) EP3648750A4 (https=)
JP (1) JP2020526515A (https=)
CN (1) CN111050757A (https=)
CA (1) CA3068917A1 (https=)
WO (1) WO2019010310A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187344A1 (en) 2017-04-03 2018-10-11 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
CA3068917A1 (en) * 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
WO2022031594A1 (en) * 2020-08-06 2022-02-10 Dianomi Therapeutics, Inc. Compositions and methods for vaccine delivery
WO2022051247A1 (en) * 2020-09-01 2022-03-10 Dianomi Therapeutics, Inc. Methods for treating or preventing inflammatory events
CN115227676B (zh) * 2022-07-04 2023-10-24 浙江大学 一种缓释mRNA的矿物包被微粒材料及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519898A (ja) * 2012-05-21 2015-07-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成自己複製ＲＮＡによるヒトｉＰＳ細胞の作製

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080317807A1 (en) * 2007-06-22 2008-12-25 The University Of Hong Kong Strontium fortified calcium nano-and microparticle compositions and methods of making and using thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9862926B2 (en) * 2011-06-27 2018-01-09 Cellscript, Llc. Inhibition of innate immune response
US20160017368A1 (en) * 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection
EP3046933B1 (en) * 2013-09-18 2019-02-27 BCN Peptides, S.A. Cortistatin analogues for the treatment of inflammatory and/or immune diseases
CA3068917A1 (en) * 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519898A (ja) * 2012-05-21 2015-07-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成自己複製ＲＮＡによるヒトｉＰＳ細胞の作製

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMALL, 2014, NO. 9, PP. 1790-1798, JPN6022029352, ISSN: 0004827815 *

Also Published As

Publication number Publication date
US20200170958A1 (en) 2020-06-04
EP3648750A4 (en) 2021-05-26
US11065208B2 (en) 2021-07-20
CN111050757A (zh) 2020-04-21
EP3648750A1 (en) 2020-05-13
US11779542B2 (en) 2023-10-10
US20210353549A1 (en) 2021-11-18
CA3068917A1 (en) 2019-01-10
WO2019010310A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
US11779542B2 (en) Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
Zhao et al. Long-term storage of lipid-like nanoparticles for mRNA delivery
Paloncýová et al. Role of ionizable lipids in SARS-CoV-2 vaccines as revealed by molecular dynamics simulations: from membrane structure to interaction with mRNA fragments
Bobba et al. Nanoparticle delivery of microRNA-146a regulates mechanotransduction in lung macrophages and mitigates injury during mechanical ventilation
US20220168231A1 (en) Synthetic lipids for mrna delivery
Shi et al. Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size
Shen et al. Application of deferoxamine in tissue regeneration attributed to promoted angiogenesis
Ito et al. Establishment of an evaluation method for gene silencing by serial pulmonary administration of siRNA and pDNA powders: naked siRNA inhalation powder suppresses luciferase gene expression in the lung
CN118634207B (zh) 一种雾化吸入用核酸-脂质纳米粒及其制备方法和应用
Lei et al. Exosome-like vesicles encapsulated with specific microRNAs accelerate burn wound healing and ameliorate scarring
Wang et al. Injectable carrier for zero-order release of salmon calcitonin
US20190358344A1 (en) Mineral coated microparticles for sustained delivery of steroids
JP2020513033A (ja) 生物学的に活性な分子を持続送達するためのミネラルコーティングされたマイクロ粒子
Nelson et al. Mineral coated microparticles doped with fluoride and complexed with mRNA prolong transfection in fracture healing
Qi et al. Metabolic Reprogramming of Cancer‐Associated Fibroblasts: Transforming Tumor Accomplices into Immunotherapeutic Allies
EP2440176A2 (en) Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylcholine
US11628227B2 (en) Mineral coated microparticles for gene delivery in chronic wound therapy
Jeon et al. Lipid nanoparticles formulated with a novel cholesterol-tailed ionizable lipid markedly increase mRNA delivery both in vitro and in vivo
JP2010511692A (ja) イオントフォレシスを通じての核酸の強化された網膜送達
Zheng et al. Microfluidic synthesis of miR-200c-3p lipid nanoparticles: targeting ZEB2 to alleviate chondrocyte damage in osteoarthritis
HK40020489A (en) Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
CN103006562B (zh) 达托霉素醇质体制剂
EP4008353A1 (en) Pharmaceutical composition for otic administration
WO2022051247A1 (en) Methods for treating or preventing inflammatory events
Murphy et al. A multifunctional nanostructured platform for localized sustained release of analgesics and antibiotics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230221